Literature DB >> 23580180

Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.

Alexandros Garouniatis1, Adamantia Zizi-Sermpetzoglou, Spyros Rizos, Alkiviadis Kostakis, Nikolaos Nikiteas, Athanasios G Papavassiliou.   

Abstract

Vascular endothelial growth factor receptor-1 (VEGFR-1) and caveolin-1 have been shown to act both as tumor-promoting and tumor-suppressing proteins in various malignancies as well as in colorectal cancer (CRC), while VEGFR-3's lymphagiogenic involvement and connection to tumor parameters has yielded heterogenic results. This study was designed to investigate the expression of these molecules in 183 human CRC tissue specimens and explore their effect in both clinicopathological parameters and disease prognosis. We also utilize our previous results regarding epidermal growth factor receptor (EGFR), c-Met, CD44v6, and focal adhesion kinase, in an attempt to further clarify their distinct role in tumor prognosis and their crosstalk. Caveolin-1 was more freely distributed in the neoplasms of the right colon and restricted towards the left and the rectal cancer samples (p = 0.022); VEGFR-3 was associated with higher nodal metastasis' status (p = 0.001) and staging (p = 0.006), and loss of VEGFR-1 predicted distant metastasis (p = 0.026) and advanced stage (p = 0.049). Prompted by previous reports, we performed all analyses also in the patient group of early (I and II) tumor stage where it was evident that VEGFR-1 was more frequently expressed in patients under 60 years old (p = 0.014) and VEGFR-3 was significantly elevated in left colon cancers (p = 0.039) and female patients (p = 0.038). Within the advanced stage (III and IV), the absence of VEGFR-1 exhibited a tendency for higher M status (p = 0.067) and lack of caveolin-1 signified worse AJCC classification (p = 0.053). Additionally, patient survival was influenced from VEGFR-3 (p = 0.019) for the whole sample, whereas subgroup analyses provided a correlation between caveolin-1 expression and improved survival in the early detection group of patients (p = 0.022). Using Cox regression for all available markers, FAK, CD44v6, and Caveolin-1 [corrected] emerged in this study as potential surrogate markers, the latter having positive prognostic significance. We further explored the multiple receptor correlations that were identified.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580180     DOI: 10.1007/s13277-013-0776-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

1.  The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.

Authors:  Vickie Hanrahan; Margaret J Currie; Sarah P Gunningham; Helen R Morrin; Prudence A E Scott; Bridget A Robinson; Stephen B Fox
Journal:  J Pathol       Date:  2003-06       Impact factor: 7.996

2.  Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities.

Authors:  J Couet; M Sargiacomo; M P Lisanti
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

3.  Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing.

Authors:  K Paavonen; P Puolakkainen; L Jussila; T Jahkola; K Alitalo
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

4.  Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma.

Authors:  M Moriyama; S Kumagai; S Kawashiri; K Kojima; K Kakihara; E Yamamoto
Journal:  Oral Oncol       Date:  1997-09       Impact factor: 5.337

5.  A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer.

Authors:  Yuriko Mori; Kun Cai; Yulan Cheng; Suna Wang; Bogdan Paun; James P Hamilton; Zhe Jin; Fumiaki Sato; Agnes T Berki; Takatsugu Kan; Tetsuo Ito; Carmit Mantzur; John M Abraham; Stephen J Meltzer
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

6.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

Authors:  R Valtola; P Salven; P Heikkilä; J Taipale; H Joensuu; M Rehn; T Pihlajaniemi; H Weich; R deWaal; K Alitalo
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

7.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

8.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

Review 9.  Caveolin-1: a tumor-promoting role in human cancer.

Authors:  Maria Shatz; Mordechai Liscovitch
Journal:  Int J Radiat Biol       Date:  2008-03       Impact factor: 2.694

10.  Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread.

Authors:  Martin Schneider; Peter Büchler; Nathalia Giese; Thomas Giese; Jörg Wilting; Markus W Büchler; Helmut Friess
Journal:  Int J Oncol       Date:  2006-04       Impact factor: 5.650

View more
  10 in total

1.  Regulation of MET-mediated proliferation of thyroid carcinoma cells by miR-449b.

Authors:  Lei Chen; Lei Xu; Gang Wang
Journal:  Tumour Biol       Date:  2015-06-06

2.  Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.

Authors:  Chunpu Li; Jing Ai; Dengyou Zhang; Xia Peng; Xi Chen; Zhiwei Gao; Yi Su; Wei Zhu; Yinchun Ji; Xiaoyan Chen; Meiyu Geng; Hong Liu
Journal:  ACS Med Chem Lett       Date:  2015-03-02       Impact factor: 4.345

Review 3.  High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis.

Authors:  HeLi Gao; Mei Guan; Zhao Sun; ChunMei Bai
Journal:  Tumour Biol       Date:  2015-01-31

4.  Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Wafaey Gomaa; Abdelbaset Buhmeida; Yousif Qari; Mohammad Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Tumour Biol       Date:  2014-06-09

5.  Involvement of lysosomal degradation in VEGF-C-induced down-regulation of VEGFR-3.

Authors:  Kyu-Yeon Han; Jin-Hong Chang; Jennifer Dugas-Ford; Jonathan S Alexander; Dimitri T Azar
Journal:  FEBS Lett       Date:  2014-10-02       Impact factor: 4.124

6.  Genistein suppresses FLT4 and inhibits human colorectal cancer metastasis.

Authors:  Xiao Xiao; Zhiguo Liu; Rui Wang; Jiayin Wang; Song Zhang; Xiqiang Cai; Kaichun Wu; Raymond C Bergan; Li Xu; Daiming Fan
Journal:  Oncotarget       Date:  2015-02-20

7.  Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.

Authors:  Caren Jayasinghe; Nektaria Simiantonaki; Charles James Kirkpatrick
Journal:  BMC Cancer       Date:  2015-03-07       Impact factor: 4.430

8.  Novel small peptides derived from VEGF125-136: potential drugs for radioactive diagnosis and therapy in A549 tumor-bearing nude mice.

Authors:  Xiang Zhang; Shibin Feng; Jie Liu; Qianwei Li; Lei Zheng; Laiping Xie; Hongmin Li; Dingde Huang
Journal:  Sci Rep       Date:  2017-06-27       Impact factor: 4.379

9.  Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor.

Authors:  Juanli Yang; Tienian Zhu; Ruijing Zhao; Dongmei Gao; Yujie Cui; Kun Wang; Yanli Guo
Journal:  Med Sci Monit       Date:  2018-01-17

10.  Flt-1-positive cells are cancer-stem like cells in colorectal carcinoma.

Authors:  Ye Huang; Yinpeng Huang; Di Liu; Tianyi Wang; Guang Bai
Journal:  Oncotarget       Date:  2017-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.